Your browser doesn't support javascript.
loading
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, Anna; Jani, Hardik; Quinones, Julian; Nunna, Naveen; O'Connell, Sarah; McDermott, Adrian B; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya; Bennett, Hamilton; Corbett, Kizzmekia S; Seder, Robert; Graham, Barney S; Stewart-Jones, Guillaume B E; Carfi, Andrea; Edwards, Darin K.
Afiliação
  • Wu K; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA. Electronic address: kai.wu@modernatx.com.
  • Choi A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Koch M; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Elbashir S; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Ma L; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Lee D; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Woods A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Henry C; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Palandjian C; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Hill A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Jani H; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Quinones J; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Nunna N; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Falcone S; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Narayanan E; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Colpitts T; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Bennett H; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Seder R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Stewart-Jones GBE; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Carfi A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Edwards DK; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA. Electronic address: darin.edwards@modernatx.com.
Vaccine ; 39(51): 7394-7400, 2021 12 17.
Article em En | MEDLINE | ID: mdl-34815117
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 / 4_TD Problema de saúde: 2_enfermedades_transmissibles / 4_pneumonia Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 / 4_TD Problema de saúde: 2_enfermedades_transmissibles / 4_pneumonia Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article